English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Melanoma is one of the most dangerous forms of cancer. The five-year survivalrate is 98% if it is detected early. However, this rate plummets to 63% forregional disease and 17% when tumors have metastasized, that is, spread todistant sites. Furthermore, the incidence of melanoma has been rising by about3% per year, whereas the incidence of cancers that are more common isdecreasing. A handful of targeted therapies have recently become available thathave finally shown real promise for treatment, but for reasons that remainunclear only a fraction of patients respond long term. These drugs oftenincrease survival by only a few months in metastatic patient groups beforerelapse occurs. More effective treatment may be possible if a diagnosis can bemade when the tumor burden is still low. Here, an overview of the currentstate-of-the-art is provided along with an argument for newer technologiestowards early point-of-care diagnosis of melanoma.

Perspective: Melanoma diagnosis and monitoring: Sunrise for melanoma therapy but early detection remains in the shade